Laurent Pharmaceuticals Receives a CAD 2.7M Financing from BioMed Propulsion Fund

Laurent Pharmaceuticals Inc. (the “Company”), a biopharmaceutical company focusing on rare diseases, today announced that it has received the final approval for a CAD 2.7M loan from the Quebec Government through its BioMed Propulsion program. This financing will help support the Company’s Phase 2 clinical study evaluating LAU-7b in adult patients with cystic fibrosis (“CF”).

NewsGuest UserDecember 5, 2019Laurent Pharmaceuticals, rare diseases, loan, Quebec Government, BioMed, BioMed Propulsion program